PATENT CLAIM ANALYSIS

Application Number: 16054451
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-11
Patent Classification: ["424", "464000"]

Abstract:
Disclosed are novel pharmaceutical compositions containing 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinol-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.

Claim (Index 1):
The pharmaceutical tablet comprising:\n a) a drug, which is 3\u2032-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2\u2032-hydroxy-[1,1\u2032-biphenyl]-3-carboxylic acid bis-(monoethanolamine); wherein, b) 90% of the drug particles have a particle size greater than 10 micron but less than 90 micron.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 96.0
- Lexical Diversity: 1.29032
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['12607330', '12607291', '12607284', '12607305', '13272367']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8024322243245012
- 35 USC 102 Novelty (BERT): 0.6289633857142052
- Combined Prediction Score: 0.7850853404634717
- Mean Citation Score: 577.546632
- Max Citation Score: 578.9488
- Similarity Product: 573.8087932963373

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test